<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4F6D5C16-9376-4E97-BEA0-72DE59AB77C9"><gtr:id>4F6D5C16-9376-4E97-BEA0-72DE59AB77C9</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Wills</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EAD69D6C-4A04-4567-8945-986175413495"><gtr:id>EAD69D6C-4A04-4567-8945-986175413495</gtr:id><gtr:firstName>Alexander</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Frater</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BB34020B-00B9-4EDE-B94D-F7F895813C8F"><gtr:id>BB34020B-00B9-4EDE-B94D-F7F895813C8F</gtr:id><gtr:firstName>Abdel GA</gtr:firstName><gtr:surname>Babiker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/79F98FBA-CEF4-4875-A822-F1521642AF2C"><gtr:id>79F98FBA-CEF4-4875-A822-F1521642AF2C</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:surname>Fidler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/84E83045-C16C-48F2-AF16-F3E4032A80B4"><gtr:id>84E83045-C16C-48F2-AF16-F3E4032A80B4</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Fisher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/46A2376B-116A-41E7-8CFE-C6431A697FD9"><gtr:id>46A2376B-116A-41E7-8CFE-C6431A697FD9</gtr:id><gtr:firstName>mark</gtr:firstName><gtr:surname>nelson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C59B90EE-E07C-4C7E-BFC8-5EAB10CE6616"><gtr:id>C59B90EE-E07C-4C7E-BFC8-5EAB10CE6616</gtr:id><gtr:firstName>Julie</gtr:firstName><gtr:surname>Fox</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/36D39D00-77E2-4E33-A8D8-BE30D7157B44"><gtr:id>36D39D00-77E2-4E33-A8D8-BE30D7157B44</gtr:id><gtr:firstName>Sabine</gtr:firstName><gtr:surname>Kinloch-de-Loes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FL00528X%2F1"><gtr:id>AF4DEE19-7B6B-44B5-ABDA-6BAC024B33FB</gtr:id><gtr:title>MICA: RIVER - Recent HIV Infection Viral Eradication Research</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L00528X/1</gtr:grantReference><gtr:abstractText>Although treatment with antiretroviral therapy (ART) for HIV infection has markedly changed the life expectancy of people living with HIV, ART alone is unable to cure infection. This is because the virus is able to remain 'dormant' or latent for the life time of the infected person in certain cells of the body called the reservoir. It is for this reason that if ART is stopped the virus returns.

Researchers have recently identified certain very rare individual cases where it appears that HIV has in fact been to some extent &amp;quot;cured&amp;quot;, through either very complicated treatment or very early ART at the time of birth.

In this study we will test whether starting ART as soon as an individual has become infected with HIV, followed by an HIV specific vaccination to strengthen the immune responses to HIV and another drug that forces virus out of the latently infected &amp;quot;reservoir&amp;quot; cells, may work in combination to reduce the number of latently infected cells. Research has shown that the fewer cells that contain 'latent viral infection' the better the chance the immune system has to control virus dividing without needing lifelong ART.

In the first place this study will test whether the combination of interventions in very recent HIV infection has the ability to make a significant reduction on the size of the viral reservoir; this is called a 'proof of concept' study and if effective may the lead onto further research.</gtr:abstractText><gtr:technicalSummary>Antiretroviral therapy (ART) has revolutionised survival in HIV infection; however, alone, ART is unable to eradicate the virus because of an inaccessible pool of infected cells in which the virus is transcriptionally silent (the proviral reservoir).Eradication of HIV from reservoirs is likely to require at least two interventions: 1) Transcriptional activation of HIV from latently infected cells, 2) elimination of these re-activated cells.

We believe that Primary HIV Infection (PHI) represents the optimal timing for reservoir perturbation - the proviral reservoir is less established than in chronic disease, likely to be more susceptible to intervention and relatively homogeneous with limited time to incorporate viral escape mutations from the comparatively well preserved immune responses.

In vitro studies showed that Histone Deacetylase Inhibitor (HDACi) agents such as Vorinostat, Panobinostat and Romidepsin target specific histones associated with HIV repression leading to activation of viral transcription. Data from a single dose and 14-day dosing of vorinostat in HIV+ individuals with chronic infection on ART showed that HDACi led to a 5-fold and 2.5-fold increase in viral transcription, respectively. However, critically, neither study reported elimination of reactivated cells. Therefore, as an adjunct to HDACi administration, we propose an immunisation strategy to stimulate HIV-specific responses that will recognise and kill re-activated &amp;quot;reservoir cells&amp;quot;. We will use a prime-boost immunisation with recombinant replication-defective chimpanzee adenovirus and modified vaccinia Ankara vaccines carrying conserved HIV sequences, previously demonstrated to induce high levels of HIV-specific, cytotoxic CD8+ T-cells.

This proof-of-concept study will test the hypothesis that a combination of HDACi-induced transcriptional activation, and potent HIV-specific T-cell immunisation at PHI, under ART suppression, will significantly reduce the proviral reservoir.</gtr:technicalSummary><gtr:potentialImpactText>Antiretroviral therapy (ART) has revolutionised survival in HIV infection. However, ART alone is unable to eradicate the virus because of an inaccessible pool of HIV infected cells in which the virus is transcriptionally silent (the proviral reservoir). In 2013, there will be &amp;gt;100,000 people living with HIV in the UK, costing &amp;gt;&amp;pound;1 billion annually. These costs are unsustainable. The most desirable goal both for individual patients and society is to understand how to eradicate HIV from the body.

Who will benefit from this research?
This research will benefit the academic community and people living with HIV (PLWH) for which a cure would represent an unprecedented step forward at times where treatment is a lifelong undertaking associated with toxicity and risk of resistance requiring treatment switch. In addition, in the absence of replicating virus the risk of onward viral transmission to sexual partners and infants would also be removed with a direct impact on the epidemic at population level. Hence, this research has the potential to benefit society at large by potentially impacting HIV incidence, as well as removing the burden of care provision for PLWH.
 
How will they benefit from this research?
 Academic Community
Several approaches have been tested in a search for an HIV cure but none has yet been able to eradicate the reservoir of virus using scalable interventions. The study will be the first to investigate a combination approach and will provide critical information about the potential of HDACi accompanied by an immune stimulation. It is clear already that interruption of viral latency will require more than ART and HDACi and even a negative result from this proof of concept study will significantly move the field forwards.
Refinement of ultra low copy HIV viral load measurement and quantification of the HIV reservoirs using new technology represents an invaluable resource for the scientific community working on elucidating the mechanism by which a curecould be developed. These technologies can then be used in other intervention trials.
The collaborators have many years of successful internationally renowned experience in the field of HIV therapeutics, vaccine and prevention. This project will add to the continuation of their expertise as well as maintaining their training and development.

 HIV infected community
The participants will have an opportunity to be involved in state-of-the-art study in an innovative area of research. Through community advisory board and interactions with patient groups, this will allow for public education and the research dissemination. Should the approach deliver a functional cure, the study participants would be the first beneficiaries of a long sought after therapy. Further, a cure would limit the known complications associated with continued HIV-mediated immune activation such as malignancy and cardiovascular disease. This would represent a significant alteration in quality of lifestyle, long-term clinical outcome and may confer a significant impact on HIV incidence at a population level.

 National Health Services
A functional cure would have a direct impact on the cost associated with the management of PLWH and associated pathologies such as cardiac diseases, cancer and neurocognitive disorders.
The research will provide a basis for clinical decision making and policy-making for governments, policy-makers and advocates to develop evidence-based policies and advocacy aiming at prioritising investments in HIV research (clinical and basic science), allowing for an efficient use of limited funds, supporting research that has a greater potential to deliver results at population level.

Timescales for the benefits to be realised
The results could lead to a Phase 2 Trial within 2 years of completion. 
Biological Samples collected during the study will contribute to a biobank that can be made available as soon as the study is completed for future investigation</gtr:potentialImpactText><gtr:fund><gtr:end>2019-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-02-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1648402</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>We currently have in development with the UCL Health Creatives an animation to help explain how HIV is currently treated, why HIV cannot be cured, and the &amp;quot;Kick and Kill&amp;quot; theory that we are investigating in the RIVER trial. This short animation will consist of animated illustrations and a recorded voice-over. Our anticipated audience for this are potential RIVER study participants, and we aim to advertise this to recruiting sites and via the CHERUB Collaboration website as a useful tool to explain the concept of the study.</gtr:description><gtr:id>D1F3B9FB-64B6-462D-BEC4-663E06BDA629</gtr:id><gtr:impact>No notable impact yet, as the animation is yet to be completed.</gtr:impact><gtr:outcomeId>56cc2cd1380a48.28151838</gtr:outcomeId><gtr:title>Animation for the RIVER trial</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHERUB: Collaboration on HIV eradication in the UK</gtr:description><gtr:id>1880DD82-BAAE-4AA4-8BB0-B09B46D1D97F</gtr:id><gtr:impact>Publications
Additional funding from British HIV Association (BHIVA)
MRC clinical fellowship
PhD students
Presentation at conferences
Subsequent collaborations with international organisations
Plenary presentations at international and national meetings</gtr:impact><gtr:outcomeId>5464d02947d067.06105782-4</gtr:outcomeId><gtr:partnerContribution>Oxford University leads the laboratory assays, King's College London the biobank tissue repository, UCL the clinical trials management through MRC CTU at UCL, Cambridge runs some of the research assays and Imperial College London leads the overall collaboration administration and patient recruitment.</gtr:partnerContribution><gtr:piContribution>Through NIHR BRC funding we have developed a collaboration on HIV eradication research which includes patient recruitment, laboratory bio-banking, scientific assays development and clinical trials management on studies such as RIVER.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHERUB: Collaboration on HIV eradication in the UK</gtr:description><gtr:id>B1A1C7EC-4E93-444F-B802-D6740E4A2091</gtr:id><gtr:impact>Publications
Additional funding from British HIV Association (BHIVA)
MRC clinical fellowship
PhD students
Presentation at conferences
Subsequent collaborations with international organisations
Plenary presentations at international and national meetings</gtr:impact><gtr:outcomeId>5464d02947d067.06105782-3</gtr:outcomeId><gtr:partnerContribution>Oxford University leads the laboratory assays, King's College London the biobank tissue repository, UCL the clinical trials management through MRC CTU at UCL, Cambridge runs some of the research assays and Imperial College London leads the overall collaboration administration and patient recruitment.</gtr:partnerContribution><gtr:piContribution>Through NIHR BRC funding we have developed a collaboration on HIV eradication research which includes patient recruitment, laboratory bio-banking, scientific assays development and clinical trials management on studies such as RIVER.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHERUB: Collaboration on HIV eradication in the UK</gtr:description><gtr:id>E47345C0-DEB6-493B-A812-E4209CD6E480</gtr:id><gtr:impact>Publications
Additional funding from British HIV Association (BHIVA)
MRC clinical fellowship
PhD students
Presentation at conferences
Subsequent collaborations with international organisations
Plenary presentations at international and national meetings</gtr:impact><gtr:outcomeId>5464d02947d067.06105782-2</gtr:outcomeId><gtr:partnerContribution>Oxford University leads the laboratory assays, King's College London the biobank tissue repository, UCL the clinical trials management through MRC CTU at UCL, Cambridge runs some of the research assays and Imperial College London leads the overall collaboration administration and patient recruitment.</gtr:partnerContribution><gtr:piContribution>Through NIHR BRC funding we have developed a collaboration on HIV eradication research which includes patient recruitment, laboratory bio-banking, scientific assays development and clinical trials management on studies such as RIVER.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>RIVER study-research partner</gtr:description><gtr:id>A050F2D4-9AAE-4062-AD2C-451739DA81E3</gtr:id><gtr:impact>The trial has just started so there are no outputs from this collaboration.</gtr:impact><gtr:outcomeId>56bc57590b7558.31454854-1</gtr:outcomeId><gtr:partnerContribution>Oxford University is a research partner and will be performing assays on trial patient samples.</gtr:partnerContribution><gtr:piContribution>Imperial College, London is the trial sponsor and provides overall project management to the award.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>RIVER study-clinical site management</gtr:description><gtr:id>8978C802-F270-4BA7-B3E9-C2A62ABF2DBF</gtr:id><gtr:impact>no outcomes as trial has just started.</gtr:impact><gtr:outcomeId>56bc58c9d07c49.40833940-1</gtr:outcomeId><gtr:partnerContribution>The MRC-CTU is responsible for the management of the 6 clinical sites, and will also provide statistical analysis for the trial.</gtr:partnerContribution><gtr:piContribution>Imperial College is the trial sponsor and responsible for the overall project management of the award.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHERUB: Collaboration on HIV eradication in the UK</gtr:description><gtr:id>A6B4DAFA-A2DA-41FB-A9E5-6DF583B7EBDA</gtr:id><gtr:impact>Publications
Additional funding from British HIV Association (BHIVA)
MRC clinical fellowship
PhD students
Presentation at conferences
Subsequent collaborations with international organisations
Plenary presentations at international and national meetings</gtr:impact><gtr:outcomeId>5464d02947d067.06105782-1</gtr:outcomeId><gtr:partnerContribution>Oxford University leads the laboratory assays, King's College London the biobank tissue repository, UCL the clinical trials management through MRC CTU at UCL, Cambridge runs some of the research assays and Imperial College London leads the overall collaboration administration and patient recruitment.</gtr:partnerContribution><gtr:piContribution>Through NIHR BRC funding we have developed a collaboration on HIV eradication research which includes patient recruitment, laboratory bio-banking, scientific assays development and clinical trials management on studies such as RIVER.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>RIVER study-research partner</gtr:description><gtr:id>413FCE47-8D04-41EE-911C-DC5C25ABCA9E</gtr:id><gtr:impact>No output/outcome as trial has recently started.</gtr:impact><gtr:outcomeId>56bc5806c97089.05137418-1</gtr:outcomeId><gtr:partnerContribution>Cambridge University is a research partner and will perform immunological assays on trial patient samples</gtr:partnerContribution><gtr:piContribution>Imperial College is the trial sponsor and provides overall management of the award.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Flyers for the RIVER trial</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>94A110A1-7518-4290-89CB-81414D8C8D48</gtr:id><gtr:impact>The RIVER study flyers have been circulated to the national HIV organisations; Terrence Higgins Trust, Positively UK and through the UKCAB mailing lists - the mailing list reaches 106 HIV related organisations and about 800 members.</gtr:impact><gtr:outcomeId>56cae3118e5257.93573706</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RIVER trial notification on Imperial College London website</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>856045A6-6477-4FBA-BEFC-9B8D0CFA3059</gtr:id><gtr:impact>The RIVER trial was first advertised on the Imperial College London website in 2013, as Dr Fidler, Principal Investigator for RIVER, is affiliated with Imperial College London.</gtr:impact><gtr:outcomeId>56caf348c5f4c1.61506064</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_26-11-2013-10-28-14</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Twitter account for the CHERUB Collaboration, including RIVER</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F26353E4-B63B-4B39-BAFB-DEDB1FFD4642</gtr:id><gtr:impact>Twitter account for the CHERUB Collaboration of which the RIVER trial is part of. The Twitter account reaches thousands of people across the world and it is one of the best ways to communicate real time news and updates regarding the associated studies.</gtr:impact><gtr:outcomeId>56cae4a193f7a0.18793939</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> Academic Health Science Centre (AHSC) seminar series, Imperial College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DBA29519-1E0B-4D24-A5AE-278F61878DE0</gtr:id><gtr:impact>Prof Fidler presented about HIV cure research public partnership at the third Academic Health Science Centre (AHSC) seminar held at Imperial College London.</gtr:impact><gtr:outcomeId>58c2c72ed5f544.22405728</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_21-9-2016-12-46-20</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation for UK CAB on the RIVER trial</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B574BF33-1945-48A9-80A0-7A925473C93F</gtr:id><gtr:impact>Dr Fidler gave a talk on HIV cure and the RIVER study to 32 UK CAB members. UK CAB is a network for community HIV treatment advocates across the UK. They provide feedback to doctors and scientists from the point of view of the patients and thus are an invaluable resource. This talk also enabled direct links be made regarding enrollment on the RIVER trial and the participating clinics.</gtr:impact><gtr:outcomeId>56cada464856d7.02699583</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Animation about the RIVER trial</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BB03E811-D37A-41CE-94B0-28815AAD76C9</gtr:id><gtr:impact>A short animation was created to assist with the recruitment into the RIVER study. It has proven to be a valuable resource.</gtr:impact><gtr:outcomeId>58c2de72829c48.53604453</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cherub.uk.net/new-animation-explaining-the-river-study-design/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with the Sunday Times</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CED49B82-9D35-4147-A850-2EAADB8FE8DC</gtr:id><gtr:impact>Professor Fidler was interviewed by the Sunday Times on HIV cure and the RIVER trial where first participant had finished the intervention. The article sparked world-wide interest in the trial.</gtr:impact><gtr:outcomeId>58c2e14e77a9d9.48563198</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British HIV and Sexual Health and HIV (BASHH)  - HIV Masterclass, Manchester</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ED824845-5B74-4CAA-8AAF-0C94664BFF8A</gtr:id><gtr:impact>Prof Fidler will present at the BASHH HIV Masterclass on HIV Cure Strategies.</gtr:impact><gtr:outcomeId>58c2da205392d4.32021821</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Pharmaceutical Society, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CD4C8F79-C1E7-40F5-BA46-8E30B0435F20</gtr:id><gtr:impact>Prof Fidler presented about HIV vaccines and cure at the Royal Society of Pharmacists.</gtr:impact><gtr:outcomeId>58c2d572a0e729.08006939</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RIVER trial press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1F91B61E-2EF5-47C8-8345-9CBA7A0A4045</gtr:id><gtr:impact>The RIVER trial officially opened for enrolment in December 2015 and this is when the press release was also published.</gtr:impact><gtr:outcomeId>56cae6e816ce64.35622792</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Association for Sexual Health and HIV (BASHH) Annual Conference, Belfast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>001EEECB-255D-47E1-A08D-AAAD70AB7D3C</gtr:id><gtr:impact>Professor Fidler has been invited to give a plenary talk at the annual BASHH conference in Belfast: &amp;quot;An update on HIV cure&amp;quot;.</gtr:impact><gtr:outcomeId>58c2db0f82a334.88030221</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Sarah Fidler interviewed on Radio 4's The World Tonight programme</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7A5F35DA-1802-4E4C-9157-886393DEEF69</gtr:id><gtr:impact>Dr Sarah Fidler was interviewed on Radio 4's The World Tonight programme to discuss the UNAIDS report and HIV cure on Wednesday, 16th July 2014.</gtr:impact><gtr:outcomeId>56d6c017751616.92911654</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AIDS and Antiviral Research Conference, Milan, Italy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2C47C99B-D683-4168-BA92-5E14075A7C36</gtr:id><gtr:impact>Professor Fidler presented an update on HIV cure and the management of acute infection at the Italian Conference on AIDS and Antiviral Research in Milan, June 2016.</gtr:impact><gtr:outcomeId>58beed5c645885.12651152</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.icar2016.it/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Sarah Fidler interviewed on the Newsnight programme on BBC2</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1C0E3B45-28D4-409F-BDBC-7B40620292C9</gtr:id><gtr:impact>Dr Sarah Fidler contributed to a discussion on the BBC's Newsnight programme about HIV cure.</gtr:impact><gtr:outcomeId>56d6c34be42243.63784536</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BHIVA Autumn Conference, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AC03EACA-E600-4FCE-89FC-CA1CE8D474C0</gtr:id><gtr:impact>Professor Fidler was invited to delivery a plenary talk on Post-treatment control at the British HIV Association (BHIVA) Annual autumn conference.</gtr:impact><gtr:outcomeId>58c2d30ef07871.21975720</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.bhiva.org/Presentations161014.aspx</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ageing with HIV Conference, European AIDS Treatment Group, Bucharest, Romania</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A15DA03E-B999-453F-A63B-AA9C134C35B7</gtr:id><gtr:impact>Professor Fidler was invited to present on treatment and cure for HIV, at the Ageing with HIV Conference, for the European AIDS Treatment Group, in Bucharest, Romania.</gtr:impact><gtr:outcomeId>58c2dc0122db65.08578810</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.ageingwithhiv.com/presentations</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>4th UK HIV and CNS Science Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A1A7CCC3-89AF-4742-822C-074B50C6C82C</gtr:id><gtr:impact>Professor Fidler will present at the 4th annual UK HIV and CNS Science Day which is held at Chandos House, London, on 17th March 2017. Presentation title &amp;quot;HIV cure and the CNS&amp;quot;.</gtr:impact><gtr:outcomeId>58c6b121393024.31327478</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.eventbrite.co.uk/e/4th-uk-hiv-and-cns-day-2017-tickets-30923450874</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at HIV Scotland on the RIVER trial</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>109A76DF-A5D9-46D5-9C18-4C855CFA8591</gtr:id><gtr:impact>Mr Damian Kelly, the Patient Advocate for the RIVER trial, gave a talk at HIV Scotland in February 2016 about the RIVER trial and CURE research. HIV Scotland is the national HIV policy organisation for Scotland. Around 100 people attended this conference and the attendees included government representatives, patients, doctors and other care providers as well as policy makers. It was an important event for all concerned and an important opportunity to advertise the RIVER trial.</gtr:impact><gtr:outcomeId>56cae144b8ed07.23172332</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Website for CHERUB Collaboration, including RIVER</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4D72F000-06F1-4415-A770-8A73AFA65A32</gtr:id><gtr:impact>The website for the CHERUB Collaboration was established in 2012. The RIVER trial is an associated trial and it is well advertised on the CHERUB website. Queries regarding enrolment on RIVER and other trials available via CHERUB, are received through the CHERUB mailing list on a weekly basis.</gtr:impact><gtr:outcomeId>56cae8a9f2b210.93647825</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012,2013,2014,2015,2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The RIVER clinical trial will be testing the co-administration of ART (Raltegravir) and Vorinostat with a novel combination intervention strategy (Chimp adenovirus vaccine and MVA ) at Primary HIV infection (PHI) to provide a proof-of-concept that the ambitious challenge of HIV eradication is achievable.</gtr:description><gtr:id>CF0D9360-BACD-4173-BF55-97FB9FA9098B</gtr:id><gtr:impact>No impacts yet as trial has just commenced.</gtr:impact><gtr:outcomeId>56d5594cc7e605.20506805</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>RIVER clinical trial</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B5EA75DB-90B9-44A6-BEAC-A294DA6470A3</gtr:id><gtr:title>Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef922613a50f9dbe25b1e6f369d66d77"><gtr:id>ef922613a50f9dbe25b1e6f369d66d77</gtr:id><gtr:otherNames>Martin GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58b40f70a9e520.41975921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>956729F0-BAC6-47E8-980A-2E85E71D0AD4</gtr:id><gtr:title>Short Communication: Lack of Effect of Maraviroc Intensification on Blood and Gut Reservoir.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/468a1f21b90b1ce6a3f01ffd8194de8e"><gtr:id>468a1f21b90b1ce6a3f01ffd8194de8e</gtr:id><gtr:otherNames>Tiraboschi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>58b40f710c6ab5.22827627</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E01E588-650B-4253-9950-EC51E5D4F9F2</gtr:id><gtr:title>Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>58b4159e90b175.45946084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36818000-2E2F-4142-B531-1B13762F680A</gtr:id><gtr:title>Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e621749d05215f018b58573cd1667e8"><gtr:id>8e621749d05215f018b58573cd1667e8</gtr:id><gtr:otherNames>Chereau F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a578c4ee8ca37.43969538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E447B1DD-C98E-4714-95D3-999E432D7772</gtr:id><gtr:title>A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a97f259eb2c28.35608914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1BA5B5B-47E6-4C52-8349-556FDDE5ABFF</gtr:id><gtr:title>Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56b87669773d40.49638092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1267C584-4E50-4476-ABCB-9DA9A21A09B5</gtr:id><gtr:title>HIV cure strategies: response to ignore the central nervous system at your patients' peril.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a97f25cba7e40.00719819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D45B7E85-4BBF-400E-B0B9-A597E4D90BCB</gtr:id><gtr:title>International AIDS Society global scientific strategy: towards an HIV cure 2016.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb5632e416ed5f0cf01ec141fe564beb"><gtr:id>cb5632e416ed5f0cf01ec141fe564beb</gtr:id><gtr:otherNames>Deeks SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>585d5ba583f175.60816146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5918895E-CE1A-40F0-A108-4F2826AD045C</gtr:id><gtr:title>Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>585d5dbf625091.34796523</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA4B1538-D3DF-4CAE-BAF6-B299E2441E0C</gtr:id><gtr:title>Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad95a7b3808261ba01ac58b32c2bea3d"><gtr:id>ad95a7b3808261ba01ac58b32c2bea3d</gtr:id><gtr:otherNames>Rutstein SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5a97f25b5c1736.93579454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB884ACF-2EFF-427E-9076-E06A42D17375</gtr:id><gtr:title>The Role of CD4+ T Follicular Helper Cells in HIV Infection: From the Germinal Center to the Periphery.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0422310b7b85faad60b4329c6ae24ec2"><gtr:id>0422310b7b85faad60b4329c6ae24ec2</gtr:id><gtr:otherNames>Thornhill JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>58b40f70807ea8.68789502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47E3751C-A5BF-40AF-AC53-21AA44BEAD0F</gtr:id><gtr:title>Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>58b4106abee278.96148775</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L00528X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>